A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Macular Telangiectasia Type 2 Clinical Trial

Official title:
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Status Completed

Clinical Trial Summary

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03319849
Study type	Interventional
Source	Neurotech Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	February 6, 2018
Completion date	September 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03316300` - A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A	Phase 3
Completed	`NCT04729972` - Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2	Phase 2
Active, not recruiting	`NCT04907084` - Serine and Fenofibrate Study in Patients With MacTel Type 2	Phase 2
Completed	`NCT01949324` - A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel	Phase 2
Not yet recruiting	`NCT06397131` - A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Phase 3